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Identifying genes that regulate bone remodeling as 
potential therapeutic targets
 
Stephen M. Krane
 
Bone remodeling, a coupled process involving bone resorption and formation, is 
initiated by mechanical signals and is controlled by local and systemic factors 
that regulate osteoblast and osteoclast differentiation and function. An excess 
of resorption over formation leads to the bone loss and increased propensity to 
fracture that is characteristic of osteoporosis. A newly described inhibitor of 
osteoblast differentiation, Ciz, interferes with bone morphogenic protein 
signaling. As a consequence, 
 
Ciz
 
-deficient mice develop increased bone mass.
 
The term osteoporosis refers to a group
of disorders characterized by low
bone mass, poor bone quality, and an
increased propensity to fracture (1).
Throughout life, bone is continuously
being remodeled with resorption of old
bone (catabolic process) performed by
osteoclasts and deposition of new bone
(anabolic process) performed by osteo-
blasts. Bone remodeling is not a random
process and takes place in focal remodel-
ing units comprising osteoblasts, osteo-
clasts, and their precursors, in which
resorption and formation are coupled.
Bone resorption is likely the initial
event that occurs in response to local
mechanical stress signals. The reduction
in bone mass in osteoporosis results
from an imbalance between resorption
and formation in which the rate of re-
sorption exceeds that of formation. It
has been suggested that osteoporosis re-
sults from a failure of resident bone cells
to respond appropriately to mechanical
load–bearing signals and to control bone
mass and architecture (2). In the major-
ity of conditions that lead to osteoporo-
sis, such as age-associated gonadal hor-
mone deficiency, remodeling rates are
high, and although bone formation and
resorption are both increased, the rate of
bone formation is insufficient to keep
up with resorption. Indeed, pharmaco-
logic suppression of bone resorption
with estrogens or bisphosphonates, the
most widely used approach to treat os-
teoporosis, converts a high bone remod-
eling state to a lower remodeling state.
This results in a net increase in bone
mineral density and a reduction in frac-
ture rate despite the coupled decrease
in bone formation. There is evidence,
however, that the apparent increase in
bone mass takes place not by increased
deposition of bone (inorganic mineral
phase plus organic matrix) but by a slow
increase in deposition of more mineral
phase within a previously mineralized
matrix (3). Alternatively, an increase in
bone mass and reduction in fracture rate
can also be achieved by intermittent ad-
ministration of parathyroid hormone,
which increases both bone formation
and resorption with formation outpac-
ing resorption (4). It is not yet certain,
however, whether the anabolic actions
of parathyroid hormone are critically
linked to its catabolic actions. Thus, the
search is still on for anabolic agents that
increase bone formation without affect-
ing resorption or, better still, agents that
increase formation yet suppress resorp-
tion. The identification of Cas-interact-
ing zinc finger protein (CIZ), in this
issue, as a protein that inhibits bone
formation without affecting resorption
suggests that agents designed to inhibit
CIZ might fit the bill (5).
 
Controls of osteoblast differentiation 
and function
 
Studies of the pathophysiology and
genetics of skeletal cell differentiation
have provided insight into the mecha-
nism by which osteoblasts arise from
mesenchymal precursors and osteoclasts
arise from hematopoietic precursors (6,
7). The differentiation of osteoblasts is
controlled by the transcription factor
Runx2 and the transcription factor os-
terix, which functions downstream of
Runx2 (6–8). In the absence of either
Runx2 or osterix, no osteoblasts are
formed. Mice and humans that carry
only a single copy of 
 
Runx2
 
 have ab-
normalities that are specific to certain
bones rather than the entire skeleton.
Formation and proliferation of preos-
teoblast cells requires signaling through
the Wnt–frizzled–Lrp5 (low density li-
poprotein receptor–related protein)–
 
 
 
-catenin signaling pathway (9), and
LRP5 deficiencies lead to the develop-
ment of osteoporosis in both mice and
humans (10, 11). The function of ma-
ture osteoblasts, including the ability to
synthesize extracellular matrix proteins,
also requires LRP5 as well as the signal-
ing protein ATF4 (Fig. 1, reference 12).
Bone morphogenetic proteins (BMPs),
members of a family of secreted growth
factors, provide important tissue-specific
signals to preosteoblasts that are essential
for full osteogenic differentiation (13, 14).
Thus, it has been possible to use a re-
porter system driven by the BMP-2
promoter to screen libraries of chemical
compounds and natural products for
potential bone anabolic agents (14).
One class of drugs identified was the
cholesterol-reducing statins, widely
used to treat patients with heart dis-
ease. There is evidence for interactions
among the pathways described. The
Wnt/
 
 
 
-catenin signaling pathway, for
example, synergizes with the BMP-2
signaling pathway (15). Antagonists and
inhibitors also function. The embry-
onic head inducer, Dickkopf1, binds to
Lrp5/6, blocks binding of Wnts, and
inhibits signaling through the 
 
 
 
-catenin
pathway (12). Thus, mutations in
human LRP5 that interfere with the
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Dickkopf1 inhibition appear to cause a
high bone mass phenotype (16). There
are also suggestions that some of the
anabolic effects of parathyroid hor-
mone (PTH) are exerted through sup-
pression of Dickkopf1 expression (17).
Leptin, a circulating factor, which
binds receptors in the hypothalmus, is
another important inhibitor of bone
formation. In a startling series of stud-
ies, it has been demonstrated that leptin
has a powerful antiosteogenic function
that is exerted via pathways distinct
from those used to regulate body
weight (6, 7, 18).
 
Controls of osteoclast differentiation 
and function
 
Osteoclast differentiation requires the
binding of macrophage colony-stimu-
lating factor to its receptor as well as
the binding of the soluble differentia-
tion factor receptor activator of NF-
 
 
 
B
ligand (RANKL) to its receptor (RANK)
on osteoclast precursor cells (19). One
of the first factors to be cloned that reg-
ulates osteoclast differentiation was os-
teoprotegerin. Osteoprotegerin, origi-
nally identified as a novel secreted
member of the TNFR super family,
was later found to inhibit spontaneous
or induced bone resorption and cause
osteopetrosis, the converse of os-
teoporosis. Osteoprotegerin acts as a
decoy receptor that binds to RANKL
and prevents it from interacting with its
receptor (Fig. 1).
RANKL and osteoprotegerin, which
are both produced by osteoblasts at
different stages of maturity (20), ac-
count for some of the signals in os-
teoblast–osteoclast communication. In
conjunction with macrophage colony-
stimulating factor, the RANK–RANKL–
osteoprotegerin system regulates os-
teoclast differentiation. Thus, mice
and humans deficient in osteoprotegerin
have a high rate of bone loss (increased
bone resorption that exceeds forma-
tion; reference 21). As in other high
turnover states, anti-resorptive agents
can still reduce both bone formation
and resorption and compensate for os-
teoprotegerin deficiency. The signal(s)
that couples resorption and formation
remains elusive, although several of the
anabolic ligands, such as BMPs and
TGF-
 
 
 
, are stored in bone matrix as
bone is formed and are released at sites
of bone resorption and can thus act on
osteoblasts and precursors in the vicin-
ity. Signals from osteoblasts to osteo-
clasts can be provided by RANKL and
osteoprotegerin. In this case, preosteo-
blasts express a high level of RANKL
relative to osteoprotegerin, which stim-
ulates osteoclast differentiation and
function. More mature osteoblasts, by
contrast, express high levels of os-
teoprotegerin relative to RANKL,
which inhibits osteoclast differentiation
and function (20).
 
The role of CIZ in bone formation
 
The protein p130
 
cas 
 
(Cas) is a docking
protein that localizes to focal adhesion
plaques (22). Signal transduction in
response to mechanical stress in both
osteoblasts and osteoclasts is mediated
by interaction of integrins in the focal
adhesion complex with components of
the extracellular matrix. Because the
SH3 domain of Cas binds to focal adhe-
sion-associated tyrosine kinase (FAK), it
was assumed that localization of Cas to
focal adhesions involves FAK. Cas also
localizes to focal adhesions in 
 
FAK
 
-
null cells, and therefore a search was
launched for other binding partners.
A novel ligand of Cas was identified
and named CIZ (Cas-interacting zinc
finger protein; reference 22). CIZ is
expressed in different mesenchymal cells,
including osteoblasts. When overex-
pressed, CIZ activates the transcription
of several genes encoding matrix me-
talloproteinases. Localization of CIZ to
focal adhesions makes it an attractive
candidate for integrating mechanical
signals, such as those induced by fluid
sheer stress, and osteoblast function,
but its pathophysiological role had not
been investigated in vivo.
In this issue, Morinobu et al. (5) re-
port that 
 
Ciz
 
 
 
/
 
  
 
mice have increased
trabecular bone mass and conclude that
Ciz normally suppresses osteoblast
activity through its interactions with
BMPs. In 
 
Ciz
 
 
 
/
 
  
 
mice, the increased
trabecular bone mass was associated
with increased rates of bone formation
based on the established method of dy-
Figure 1. Cells and ligands in skeletal remodeling. Interactions in bone formation and resorption 
among osteoblasts and osteoclasts and some factors that modulate their differentiation and function. 
OPG, osteoprotegerin.
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namic histomorphometry, which mea-
sures the distance between timed sys-
temic pulses of calcein, a fluorescent
marker that binds to newly mineralized
bone. Bone resorption was not affected
in 
 
Ciz
 
 
 
/
 
  
 
mice, indicating no suppres-
sion of remodeling. Furthermore, in
bone marrow cultures from 
 
Ciz
 
 
 
/
 
 
 
mice, levels of alkaline phosphatase ac-
tivity (a marker for functioning osteo-
blasts) were increased and, in long-term
cultures, more mineralized nodules were
formed. Nodule formation serves as a
cell culture model for deposition of
mineralized bone matrix. Consistent
with the results of the histomorphome-
try, Morinobu et al. (5) found that there
was no difference in the generation of
osteoclasts in 
 
Ciz
 
    
 
and wild-type mar-
row cultures. Based in part on earlier
work (23), the authors postulated that
the effects of Ciz
 
 
 
deficiency could be
exerted through the BMP pathway and,
indeed, they demonstrated that effects
of BMP-2 on alkaline phosphatase ac-
tivity were greater in bone marrow cul-
tures from 
 
Ciz
 
    
 
mice compared with
wild-type mice. Finally, they showed
that more orthotopic bone is produced
in vivo after intracranial injection of re-
combinant BMP-2 in 
 
Ciz
 
    
 
mice than
is produced in wild-type mice.
With respect to mechanisms of BMP
antagonism, Morinobu et al. (5) hy-
pothesized that Ciz acts by interfering
with BMP receptor signaling by acting
as an inhibitory Smad protein (Smads
belong to a family of proteins that relay
signals from the BMP receptor to target
genes in the nucleus) rather than inter-
fering with BMP binding to its recep-
tor. Another factor (Tob) also inhibits
osteoblast function by acting as a Smad
suppressor (24). Whether Ciz can in-
hibit osteoblast function by affecting
the Wnt–
 
 
 
–catenin signaling pathway
in synergy with BMP signaling remains
to be shown.
The study of the Ciz-deficient mice
is a further illustration of the progress
over the past two decades in under-
standing skeletal biology. It is possible
that molecular and genetic observations,
including those described here, will lead
to identification of useful new thera-
peutic targets for treatment of common
bone diseases such as osteoporosis. Even
though anti-resorptive agents have great
efficacy, there is potential usefulness for
the development of anabolic agents that
could increase bone formation without
affecting resorption, as mentioned ear-
lier. It is conceivable that drugs de-
signed to antagonize CIZ could help to
achieve this goal.
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